US20220160641A1 - Capsule with internal diaphragm for improved bioavailability - Google Patents

Capsule with internal diaphragm for improved bioavailability Download PDF

Info

Publication number
US20220160641A1
US20220160641A1 US17/488,787 US202117488787A US2022160641A1 US 20220160641 A1 US20220160641 A1 US 20220160641A1 US 202117488787 A US202117488787 A US 202117488787A US 2022160641 A1 US2022160641 A1 US 2022160641A1
Authority
US
United States
Prior art keywords
oil
compartment
liquid
ingredient
capsule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US17/488,787
Inventor
Tobias Johan Louw
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Combocap Inc
Original Assignee
Combocap Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Combocap Inc filed Critical Combocap Inc
Priority to US17/488,787 priority Critical patent/US20220160641A1/en
Publication of US20220160641A1 publication Critical patent/US20220160641A1/en
Assigned to COMBOCAP, INC. reassignment COMBOCAP, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: LOUW, Tobias Johan
Abandoned legal-status Critical Current

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4808Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/01Hydrocarbons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/192Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203Retinoic acids ; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355Tocopherols, e.g. vitamin E
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365Lactones
    • A61K31/375Ascorbic acid, i.e. vitamin C; Salts thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4458Non condensed piperidines, e.g. piperocaine only substituted in position 2, e.g. methylphenidate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525Isoalloxazines, e.g. riboflavins, vitamin B2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/60Salicylic acid; Derivatives thereof
    • A61K31/612Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
    • A61K31/616Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/06Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/18Iodine; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/26Iron; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/42Phosphorus; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66Microorganisms or materials therefrom
    • A61K35/74Bacteria
    • A61K35/741Probiotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/53Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/71Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K2035/11Medicinal preparations comprising living procariotic cells
    • A61K2035/115Probiotics

Definitions

  • Embodiments described herein are directed to a multi-compartment capsule comprising a body; a diaphragm, having two sidewalls and a bottom, extending into the body and defining a first compartment between an outer surface of the diaphragm and an inner surface of the body, adapted to hold an oil; and a cap mounted to an outer surface of the body and opposed to the diaphragm, and defining a second compartment between an inner surface of the diaphragm and the cap, adapted to hold an ingredient which has increased bioavailability after exposure to the oil; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body.
  • the capsule is a size 00 capsule.
  • the first compartment is hermetically sealed by the diaphragm.
  • the oil is selected from the group consisting of omega-3 oil, red palm oil, fish oil, krill oil, walnut oil, saw palmetto oil, castor oil, garlic oil, flaxseed oil, canola oil, soybean oil, cannabis oil, argan oil, coconut oil, peppermint oil, evening primrose oil, oregano oil, emu oil, cod liver oil, algae oil, grape seed oil, rose oil, clove oil, vitamin E oil, blueberry seed oil, raspberry seed oil, pumpkin seed oil, hemp oil, alpha-linolenic acid, and combinations thereof.
  • the omega-3 oil is selected from the group consisting of alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, krill oil, fish oil, walnut oil, flaxseed oil, canola oil, soybean oil, and combinations thereof.
  • the ingredient is an oil, a liquid, a powder, a granule, a semi-solid, a gel, a beadlet, a microbead, a liquid, or a combination thereof.
  • the ingredient is an oil, a probiotic, a botanical, an herbal extract, a digestive enzyme, a vitamin, a carotenoid, a collagen, a medicament, or a combination thereof.
  • the bottom of the diaphragm may be flattened. In some embodiments, the bottom of the diaphragm may be curved. In some embodiments, the bottom of the diaphragm may be substantially or partially flattened.
  • the oil comprises an omega-3 oil and the ingredient is a multivitamin powder, or a multivitamin powder and coenzyme Q10.
  • the oil comprises an omega-3 oil and the ingredient is a statin, or a statin and coenzyme Q10.
  • the oil comprises an omega-3 oil and the ingredient is vitamin K2.
  • the oil comprises alpha-linolenic acid and the ingredient is selected from chromium, or chromium and coenzyme Q10.
  • the oil is saw palmetto oil and the ingredient is a liothyronine sodium (T3) powder.
  • the oil is red palm oil, and the ingredient is selected from vitamin D, vitamin K2, a multivitamin or a combination thereof.
  • the oil is an omega-3 oil
  • the ingredient is selected from aspirin, a statin, or a combination thereof.
  • Some embodiments described herein are directed to a multi-compartment capsule comprising a body; a diaphragm, having two sidewalls and a bottom, extending into the body and defining a first compartment between an outer surface of the diaphragm and an inner surface of the body, adapted to hold an ingredient; and a cap mounted to an outer surface of the body and opposed to the diaphragm, and defining a second compartment between an inner surface of the diaphragm and the cap, adapted to hold an oil; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body.
  • the second compartment is sealed to prevent oil leakage.
  • the ingredient has increased bioavailability upon exposure to the oil.
  • FIG. 1 illustrates a cross-sectional view of a capsule of embodiments herein wherein the first (lower) compartment has a volume of about 423 mm 3 and the second (upper) compartment has a volume of about 497 mm 3 , and wherein the first compartment comprises an oil and the second compartment comprises an ingredient.
  • FIG. 2 illustrates a cross-sectional view of a capsule of embodiments herein wherein the first (lower) compartment has a volume of 743 mm 3 and the second (upper) compartment has a volume of 176 mm 3 , and wherein the first compartment comprises an oil and the second compartment comprises an ingredient.
  • FIG. 3 illustrates a cross-sectional view of a capsule of embodiments herein with a flattened bottom, wherein each compartment comprises a solid ingredient.
  • FIGS. 4A, 4B, and 4C illustrate standard and elongated TORPAC capsule sizes, which may be used in some embodiments described herein.
  • the term “about” means plus or minus 10% of the numerical value of the number with which it is being used. Therefore, about 50 mg means in the range of 45 mg-55 mg.
  • patient or “subject” as used herein is an animal, particularly a human, suffering from an unwanted disease or condition that may be treated by the therapeutics and/or compositions described herein.
  • the term “medicament” or “therapeutic” means an agent used to treat, combat, ameliorate, prevent or improve an unwanted condition or disease of a subject.
  • a “therapeutically effective amount” or “effective amount” of a composition is an amount necessary or sufficient to achieve the desired result.
  • the activity contemplated by the embodiments herein includes medically therapeutic, cosmetically therapeutic and/or prophylactic treatment, as appropriate.
  • a therapeutically effective amount of the compound of embodiments herein is typically an amount such that when it is administered in a physiologically tolerable excipient composition, it is sufficient to achieve an effective systemic concentration or local concentration in or on the tissue to achieve the desired therapeutic or clinical outcome.
  • treat refers to therapeutic treatment, cosmetic treatment, and/or prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder, or disease, or to obtain beneficial or desired clinical results.
  • beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder, or disease; stabilization (i.e., not worsening) of the state of the condition, disorder, or disease; delay in onset or slowing of the progression of the condition, disorder, or disease; amelioration of the condition, disorder, or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder, or disease.
  • Treatment includes eliciting a clinically significant response without excessive levels of side effects.
  • the term “consists of” or “consisting of” means that the formulation includes only the elements, steps, or ingredients specifically recited in the particular claimed embodiment or claim.
  • the term “consisting essentially of” or “consists essentially of” means that the only active pharmaceutical ingredient in the formulation or method that treats the specified condition is the specifically recited therapeutic in the particular embodiment or claim.
  • Capsules are typically manufactured in certain standard sizes, such as TORPAC sizes, referred to as a capsule size designated by numerals, such as 000, 00, etc. Such capsules typically have two parts: a cap and a body, which are bonded or fitted together. One of the most common sizes is the 00 capsule.
  • the typical size 00 capsule in common with other capsules, has a standardized nominal volume. For instance, a size 00 capsule has a volume of approximately 0.95 milliliters.
  • the multi-compartment capsule is a size 00 capsule.
  • the capsule size may be size 000, size 0, size 1, size 2, size 3, size 4, or size 5, or any non-standard size in between these sizes.
  • the capsule size may be elongated (“EL”), such that the size may be, for example, 00 EL.
  • the elongation may be to any standard length or to a non-standard length.
  • the elongated capsule may add from about 50 mm 3 to about 150 mm 3 of additional volume to the first compartment, the second compartment, or a combination thereof.
  • the elongated capsule may add about 110 mm 3 of additional volume to the first compartment, the second compartment, or a combination thereof.
  • the diaphragm's diameter it may be possible to insert a longer diaphragm into the capsule, thereby changing the available volumes in both the first and second compartments.
  • scaling the dimensions of the multi-compartment capsule described herein may result in a larger or smaller capsule with substantially the same ratios as described herein. In some embodiments, scaling the dimensions of the multi-compartment capsule described herein may result in a larger or smaller capsule with ratios different from those described herein.
  • Exemplary benefits of such two-compartment capsules may include increased patient compliance, a double-chamber controlled release, increased efficacy or bioavailability of ingredients due to co-administration, increased stability, and the ability to formulate difficult combinations of ingredients into one capsule, such as incompatible actives which can now be co-administered.
  • the one or more ingredients delivered in such a capsule may be ingredients which have improved bioavailability when dissolved in one or more oils.
  • Embodiments described herein are directed to a multi-compartment capsule comprising a body; a diaphragm, having two sidewalls and a bottom, extending into the body and defining a first compartment between an outer surface of the diaphragm and an inner surface of the body; and a cap mounted to an outer surface of the body and opposed to the diaphragm, and defining a second compartment between an inner surface of the diaphragm and the cap; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body.
  • the capsule is a size 00 capsule.
  • the multi-compartment capsule may comprise a body; a diaphragm, having two sidewalls and a bottom, extending into the body and forming a first compartment defined by a first surface of the diaphragm and the body; and a cap mounted to the body and opposed to the diaphragm, the cap forming a second compartment defined by an opposing surface of the diaphragm and the cap; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body; and wherein the first compartment and the second compartment are each adapted to hold one or more solid ingredients.
  • the first compartment is hermetically sealed by the diaphragm.
  • the one or more solid ingredients comprises an oil, a liquid, a powder, a granule, a semi-solid, a microbead, a beadlet, or a combination thereof.
  • the bottom of the diaphragm may be flattened. A flatter bottom may allow for more volume in the lower compartment. In some embodiments, the bottom of the diaphragm may be curved. In some embodiments, the bottom of the diaphragm may be substantially or partially flattened.
  • the contents of the first compartment and the contents of the second compartment may be released simultaneously.
  • This simultaneous release may occur because each end of the multi-compartment capsule comprises the same or substantially the same material composition and thickness, such that when the capsule is digested, both compartments are degraded simultaneously.
  • This simultaneous release may be advantageous in some embodiments wherein the contents of the first compartment and the contents of the second compartment may provide improved bioavailability or other synergistic effects when combined by such a release.
  • the first compartment comprises an oil.
  • the second compartment comprises an ingredient.
  • the second ingredient is adapted to hold an ingredient which has increased bioavailability after exposure to the oil.
  • the first compartment comprises an ingredient having increased bioavailability after exposure to oil and the second compartment comprises an oil. Exemplary formulations described below could be used with oil in either compartment.
  • the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body.
  • the capsule is a size 00 capsule.
  • the first compartment is hermetically sealed by the insertion and sealing of the diaphragm into the capsule body.
  • the bottom of the diaphragm may be flattened. In some embodiments, the bottom of the diaphragm may be curved. In some embodiments, the bottom of the diaphragm may be substantially or partially flattened.
  • the oil is selected from the group consisting of omega-3 oil, red palm oil, fish oil, krill oil, walnut oil, saw palmetto oil, castor oil, garlic oil, flaxseed oil, canola oil, soybean oil, cannabis oil, argan oil, coconut oil, peppermint oil, evening primrose oil, oregano oil, emu oil, cod liver oil, algae oil, grape seed oil, rose oil, clove oil, vitamin E oil, blueberry seed oil, raspberry seed oil, pumpkin seed oil, hemp oil, alpha-linolenic acid, conjugated linoleic acid, docosahexaenoic acid, ginger oil, lavender oil, and combinations thereof.
  • the omega-3 oil is selected from the group consisting of alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, krill oil, fish oil, walnut oil, flaxseed oil, canola oil, soybean oil, and combinations thereof.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the oil may comprise a form or derivative of vitamin E
  • the oil may comprise from about 10 mg to about 500 mg of a form or derivative of vitamin E
  • the form or derivative of vitamin E may be a tocotrienol, such as, for example, alpha tocotrienol, beta tocotrienol, gamma tocotrienol, delta tocotrienol, or any combination thereof.
  • the ingredient is an oil, a liquid, a powder, a granule, a semi-solid, a gel, a beadlet, a microbead, a liquid, or a combination thereof.
  • the ingredient is an oil, a probiotic, a botanical, an herbal extract, a digestive enzyme, a vitamin, a carotenoid, a collagen, a medicament, or a combination thereof.
  • the ingredient may comprise alpha-carotene, beta-carotene, biotin, cadmium, caffeine, calcium, cinnamon, copper, curcumin, dexmethylphenidate, dicalcium phosphate, docosahexaenoic acid, folic acid, frankincense, glucosamine, gymnema, gymnema extract, iodine, iron, linoleic acid, lipoic acid, LOWAT, lutein, lycopene, magnesium, magnesium stearate, manganese, melatonin, molybdenum, niacin, oleic acid, palmitic, panthothenic acid, passion flower, phosphorus, a plant sterol, resvida, selenium, squalene, ginseng, tocopherols, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin K, zinc, or a combination thereof.
  • the ingredient comprises a pharmaceutical agent.
  • the pharmaceutical agent is selected from the group consisting of aspirin, a statin, ipriflavone, cohosh, castus, coenzyme Q10 (CoQ10), gauifenesin, althea root, antimony pentasulfide, creosote, guaiacolsulfonate, ipecacuanha (syrup of ipecac), levoverbenone, potassium iodide, senega, tyloxapol, ammonium chloride, salbutamol, albuterol, levosalbutamol, levalbuterol, pirbuterol, epinephrine, ephedrine, terbutaline, salmeterol, clenbuterol, formoterol, bambuerol, indacaterol, ephrinesulfate, ticlopidine, clopidogre
  • the ingredient comprises aspirin. In some embodiments, the aspirin comprises from about 10 mg to about 500 mg. In some embodiments, the aspirin comprises from about 81 mg to about 324 mg. In some embodiments, one of the first or second compartment comprises aspirin in an amount of about 10 mg to about 500 mg.
  • the ingredient comprises a statin.
  • the statin may be selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and combinations thereof.
  • the statin may be in an amount of about 1 mg to about 100 mg. In some embodiments, the statin may be in an amount of about 5 mg to about 40 mg. In some embodiments, one of the first or second compartment comprises a statin in an amount of about 1 mg to about 100 mg.
  • the first compartment comprises aspirin in an amount of about 10 mg to about 500 mg and the second compartment comprises an oil in an amount of about 10 mg to about 2000 mg.
  • the oil is an omega-3 oil.
  • the capsule may include omega-3 oil with or without red palm oil in the first compartment, and CoQ10 in the second compartment.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the red palm oil may be in an amount of about 10 mg to about 2000 mg.
  • the CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • the oil comprises an omega-3 oil and the ingredient is a multivitamin, or a multivitamin and coenzyme Q10.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • the multivitamin may be in an amount of about 1 mg to about 5000 mg.
  • the oil comprises an omega-3 oil and the ingredient is a statin, or a statin and coenzyme Q10.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the statin in an amount of about 1 mg to about 100 mg.
  • the CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • the oil comprises an omega-3 oil and the ingredient is vitamin K2.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the vitamin K2 may be in an amount of about 10 mcg to about 1000 mcg.
  • the oil comprises alpha-linolenic acid and the ingredient is selected from chromium, or chromium and coenzyme Q10.
  • the alpha linolenic acid may be in an amount of about 10 mg to about 500 mg.
  • the chromium may be in an amount of about 10 mcg to about 1000 mcg.
  • the CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • the oil is saw palmetto oil and the ingredient is liothyronine sodium (T3).
  • the saw palmetto oil may be in an amount of about 10 mg to about 1000 mg.
  • the liothyronine sodium may be in an amount of about 5 mcg to about 500 mcg.
  • the oil is red palm oil, and the ingredient is selected from vitamin D, vitamin K2, a multivitamin or a combination thereof.
  • the red palm oil may be in an amount of about 10 mg to about 2000 mg.
  • the vitamin D may be in an amount of about 10 IU to about 3000 IU.
  • the vitamin K2 may be in an amount of about 10 mcg to about 1000 mcg.
  • the multivitamin may be in an amount of about 1 mg to about 5000 mg.
  • the oil is red palm oil
  • the ingredient is selected from lutein, lycopene, biotin, selenium, selenium (methionine), zinc, zinc (glyconate), or a combination thereof.
  • the red palm oil may be in an amount of about 10 mg to about 2000 mg.
  • the lutein may be in an amount of about 1 mg to about 30 mg.
  • the lycopene may be in an amount of about 1 mg to about 30 mg.
  • the biotin may be in an amount of about 0.01 mg to about 10 mg.
  • the selenium or selenium (methionine) may be in an amount of about 1 mcg to about 200 mcg.
  • the zinc or zinc (glyconate) may be in an amount of about 1 mg to about 45 mg.
  • the oil is an omega-3 oil and the ingredient is selected from frankincense, gymnema, gymnema extract, cinnamon, chromium, chromium (picolinate), vitamin B6, vitamin B12, or a combination thereof.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the frankincense may be in an amount of about 1 mg to about 500 mg.
  • the gymnema or gymnema extract may be in an amount of about 10 mg to about 1000 mg.
  • the cinnamon may be in an amount of about 10 mg to about 1000 mg.
  • the chromium or chromium (picolinate) may be in an amount of about 10 mg to about 1000 mg.
  • the vitamin B6 may be in an amount of about 10 mg to about 1000 mg.
  • the vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg.
  • the oil is an omega-3 oil
  • the ingredient is selected from resvida, lipoic acid, CoQ10, folic acid, vitamin B6, vitamin B12, or a combination thereof.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the resvida may be in an amount of about 10 mg to about 1000 mg.
  • the amount of lipoic acid may be in an amount of about 1 mg to about 1000 mg.
  • the CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • the folic acid may be in an amount of about 0.1 mcg to about 1000 mcg.
  • the vitamin B6 may be in an amount of about 10 mg to about 1000 mg.
  • the vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg.
  • the oil is selected from krill oil, red palm oil, or a combination thereof, and the ingredient is selected from oleic acid, linoleic acid, tocotrienols, tocopherols, beta-carotene, alpha-carotene, squalene, a plant sterol, CoQ10, a multivitamin, or a combination thereof.
  • the krill oil may be in an amount of about 10 mg to about 2000 mg.
  • the red palm oil may be in an amount of about 10 mg to about 2000 mg.
  • the oleic acid may be in an amount of about 10 mg to about 1000 mg.
  • the linoleic acid may be in an amount of about 1 mg to about 1000 mg.
  • the tocotrienols may be in an amount of about 1 mg to about 1000 mg.
  • the tocopherols may be in an amount of about 1 mg to about 1000 mg.
  • the beta-carotene may be in an amount of about 1 mg to about 1000 mg.
  • the alpha-carotene may be in an amount of about 1 mg to about 1000 mg.
  • the squalene may be in an amount of about 0.1 mg to about 1000 mg.
  • the plant sterol may be in an amount of about 1 mg to about 1000 mg.
  • the CoQ10 may be in an amount of about 0.01 mg to about 1000 mg.
  • the multivitamin may be in an amount of about 1 mg to about 5000 mg.
  • the oil is selected from krill oil, an omega-3 oil such as, for example, docosahexaenoic acid (DHA), or a combination thereof, and the ingredient is selected from vitamin C, zinc, dicalcium phosphate, vitamin D, vitamin K, magnesium, calcium, or a combination thereof.
  • the krill oil may be in an amount of about 10 mg to about 2000 mg.
  • the DHA may be in an amount of about 10 mg to about 2000 mg.
  • the vitamin C may be in an amount of about 1 mg to about 1000 mg.
  • the zinc may be in an amount of about 1 mg to about 1000 mg.
  • the dicalcium phosphate may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin D may be in an amount of about 10 IU to about 3000 IU.
  • the vitamin K may be in an amount of about 10 mcg to about 1000 mcg.
  • the magnesium may be in an amount of about 0.1 mg to about 1000 mg.
  • the calcium may be in an amount of about 1 mg
  • the oil is krill oil
  • the ingredient is selected from a multivitamin, CoQ10, vitamin A, vitamin D, vitamin D3, vitamin E, biotin, folic acid, niacin, panthothenic acid, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin K, calcium, chromium, copper, iodine, magnesium, magnesium stearate, manganese, molybdenum, phosphorus, selenium, zinc, or a combination thereof.
  • the krill oil may be in an amount of about 10 mg to about 2000 mg.
  • the multivitamin may be in an amount of about 1 mg to about 5000 mg.
  • the CoQ10 may be in an amount of about 0.01 mg to about 1000 mg.
  • the vitamin A may be in an amount of about 10 IU to about 4000 IU.
  • the vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU.
  • the vitamin E may be in amount of about 10 IU to about 3000 IU.
  • the biotin may be in an amount of about 10 mcg to about 1000 mcg.
  • the folic acid may be in an amount of about 0.1 mcg to about 1000 mcg.
  • the niacin may be in an amount of about 1 mg to about 1000 mg.
  • the panthothenic acid may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin B1 may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin B2 may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin B2 may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin B6 may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg.
  • the vitamin C may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin K may be in an amount of about 10 mcg to about 1000 mcg.
  • the calcium may be in an amount of about 1 mg to about 1000 mg.
  • the chromium may be in an amount of about 1 mcg to about 1000 mcg.
  • the copper may be in an amount of about 0.1 mg to about 100 mg.
  • the iodine may be in an amount of about 0.01 mg to about 100 mg.
  • the magnesium may be in an amount of about 0.1 mg to about 1000 mg.
  • the magnesium stearate may be in an amount of about 0.1 mg to about 1000 mg.
  • the manganese may be in an amount of about 0.1 mg to about 100 mg.
  • the molybdenum may be in an amount of about 1 mcg to about 1000 mcg.
  • the phosphorous may be in an amount of about 1 mg to about 100 mg.
  • the selenium may be in an amount of about 1 mcg to about 200 mcg.
  • the zinc may be in an amount of about 1 mg to about 1000 mg.
  • the oil is red palm oil
  • the ingredient is selected from ginseng, CoQ10, vitamin B12, caffeine, caffeine beadlets, or a combination thereof.
  • the red palm oil may be in an amount of about 10 mg to about 2000 mg.
  • the ginseng may be in an amount of about 10 mg to about 1000 mg.
  • the CoQ10 may be in an amount of about 0.01 mg to about 1000 mg.
  • the vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg.
  • the caffeine or caffeine beadlets may be in an amount of about 1 mg to about 1000 mg.
  • the oil is krill oil, and the ingredient is selected from vitamin D, vitamin D3, calcium, or a combination thereof.
  • the krill oil may be in an amount of about 10 mg to about 2000 mg.
  • the vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU.
  • the calcium may be in an amount of about 1 mg to about 1000 mg.
  • the oil is an omega-3 oil
  • the ingredient is a probiotic.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the probiotic may be in an amount of about 1 million to about 100 million CFUs.
  • the oil is krill oil, and the ingredient is selected from vitamin K2, glucosamine, collagen, UC2 collagen, or a combination thereof.
  • the krill oil may be in an amount of about 10 mg to about 2000 mg.
  • the vitamin K2 may be in an amount of about 0.01 mg to about 100 mg.
  • the glucosamine may be in an amount of about 10 mg to about 1000 mg.
  • the collagen or UC2 collagen may be in amount of about 1 mg to about 1000 mg.
  • the oil is an omega-3 oil such as, for example, alpha-linolenic acid (ALA), and the ingredient is selected from caffeine, caffeine beadlets, or a combination thereof.
  • ALA alpha-linolenic acid
  • the ALA may be in an amount of about 10 mg to about 2000 mg.
  • the caffeine or caffeine beadlets may be in an amount of about 1 mg to about 1000 mg.
  • the oil is ginger oil and the ingredient is curcumin.
  • the ginger oil may be in an amount of about 10 mg to about 2000 mg, and the circumin may be in an amount of about 10 mg to about 1000 mg.
  • the oil is an omega-3 oil
  • the ingredient is selected from vitamin D, vitamin D3, vitamin E, folic acid, vitamin B2, vitamin B6, vitamin B12, vitamin C, iron, dicalcium phosphate, or a combination thereof.
  • the omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • the vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU.
  • the vitamin E may be in an amount of about 1 IU to about 3000 IU.
  • the folic acid may be in an amount of about 0.1 mcg to about 1000 mcg.
  • the vitamin B2 may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin B6 may be in an amount of about 1 mg to about 1000 mg.
  • the vitamin B12 may be in an amount of about 1 mcg to about 1000 mcg.
  • the vitamin C may be in an amount of about 1 mg to about 1000 mg.
  • the iron may be in an amount of about 1 mg to about 1000 mg.
  • the dicalcium phosphate may be in an amount of about 1 mg to about 1000 mg.
  • the oil is krill oil and the ingredient is selected from vitamin D, vitamin D3, vitamin K2, vitamin E, vitamin E tocotrienols, or a combination thereof.
  • the krill oil may be in an amount of about 10 mg to about 2000 mg.
  • the vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU.
  • the vitamin K2 may be in an amount of about 0.01 mg to about 100 mg.
  • the vitamin E or vitamin E tocotrienols may be in an amount of about 10 mg to about 1000 mg.
  • the oil is lavender oil
  • the ingredient is selected from melatonin, passion flower, lemon, lemon extract, or a combination thereof.
  • the lavender oil may be in an amount of about 10 mg to about 2000 mg.
  • the melatonin may be in an amount of about 1 mg to about 1000 mg.
  • the passion flower may be in an amount of about 10 mg to about 1000 mg.
  • the lemon or lemon extract may be in an amount of about 10 mg to about 1000 mg.
  • the oil is conjugated linoleic acid (CLA), and the ingredient is selected from piper betle leaf, dolichos bilforus seed extract, or a combination thereof, such as LOWAT.
  • CLA conjugated linoleic acid
  • the CLA may be in an amount of about 10 mg to about 2000 mg.
  • the piper betle leaf, dolichos bilforus seed extract, or combination thereof, such as LOWAT may be in an amount of about 10 mg to about 1000 mg.
  • the oil is krill oil, and the ingredient is aspirin.
  • the krill oil may be in an amount of about 10 mg to about 2000 mg, and the aspirin may be in an amount of about 10 mg to about 500 mg.
  • the first compartment and the second compartment each has sufficient volume to administer a therapeutically effective dose of the oil and the ingredient, respectively.
  • Table 1 below lists some possible combinations of ingredients which may be found in some embodiments. It is to be understood that any of the ingredients within Table 1 may be found in any combination, and may be found in either compartment of the capsule described herein. It is to be further understood that the embodiments described in Table 1 are not meant to be limiting, but are merely illustrative.
  • Second compartment About 10 mg to about 500 mg of aspirin About 10 mg to about 2000 mg of an oil About 10 mg to about 500 mg of aspirin About 10 mg to about 2000 mg of an omega-3 oil About 10 mg to about 2000 mg of an About 10 mg to about 1000 mg of CoQ10 omega-3 oil; and/or About 10 mg to about 2000 mg of red palm oil About 10 mg to about 2000 mg of an About 1 mg to about 100 mg of a statin; omega-3 oil and/or About 10 mg to about 1000 mg of CoQ10 About 10 mg to about 2000 mg of an About 10 mcg to about 1000 mcg of omega-3 oil vitamin K2 About 10 mg to about 500 mg of alpha About 10 mcg to about 1000 mcg of linolenic acid chromium; and/or About 10 mg to about 1000 mg of CoQ10 About 10 mg to about 1000 mg of saw About 5 mcg to about 500 mcg of palmetto oil liothyronine sodium About 10 mg to about 2000 mg of red About
  • Table 2 below shows various dimensions of standard and elongated TORPAC capsule sizes, which may be used in some embodiments described herein.
  • Table 3 below shows additional dimensions of standard and elongated TORPAC capsule sizes, which may be used in some embodiments described herein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A multi-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an ingredient, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an oil. A two-compartment capsule may include a body, a diaphragm between, which seals off the body and provides a first compartment to hold an oil, and a cap applied to the body whereby a space between the inner portion of the cap and the diaphragm defines a second compartment for holding an ingredient. The ingredient may have increased bioavailability after exposure to the oil. This disclosure also provides particular formulations for use in such a capsule.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of U.S. application Ser. No. 15/767,010, filed Apr. 9, 2018, entitled “Capsule with International Diaphragm for Improved Bioavailability,” which is a U.S. national stage filing under 35 U.S.C. § 371 of International Application No. PCT/US2016/056285 filed Oct. 10, 2016 entitled “Capsule with Internal Diaphragm for Improved Bioavailability,” which claims priority to and benefit of U.S. Provisional Application No. 62/239,435 filed Oct. 9, 2015, entitled “Capsule with Volume-Adjustable Internal Diaphragm,” U.S. Provisional Application No. 62/239,454 filed Oct. 9, 2015, entitled “Capsule with Internal Diaphragm for Improved Bioavailability,” and U.S. Provisional Application No. 62/239,442 filed Oct. 9, 2015, entitled “Capsule with Internal Diaphragm and Solid Ingredients.” The contents of each of these applications are hereby incorporated herein by reference in their entireties.
  • SUMMARY
  • Embodiments described herein are directed to a multi-compartment capsule comprising a body; a diaphragm, having two sidewalls and a bottom, extending into the body and defining a first compartment between an outer surface of the diaphragm and an inner surface of the body, adapted to hold an oil; and a cap mounted to an outer surface of the body and opposed to the diaphragm, and defining a second compartment between an inner surface of the diaphragm and the cap, adapted to hold an ingredient which has increased bioavailability after exposure to the oil; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body. In some embodiments, the capsule is a size 00 capsule. In some embodiments, the first compartment is hermetically sealed by the diaphragm.
  • In some embodiments, the oil is selected from the group consisting of omega-3 oil, red palm oil, fish oil, krill oil, walnut oil, saw palmetto oil, castor oil, garlic oil, flaxseed oil, canola oil, soybean oil, cannabis oil, argan oil, coconut oil, peppermint oil, evening primrose oil, oregano oil, emu oil, cod liver oil, algae oil, grape seed oil, rose oil, clove oil, vitamin E oil, blueberry seed oil, raspberry seed oil, pumpkin seed oil, hemp oil, alpha-linolenic acid, and combinations thereof.
  • In some embodiments, the omega-3 oil is selected from the group consisting of alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, krill oil, fish oil, walnut oil, flaxseed oil, canola oil, soybean oil, and combinations thereof.
  • In some embodiments, the ingredient is an oil, a liquid, a powder, a granule, a semi-solid, a gel, a beadlet, a microbead, a liquid, or a combination thereof.
  • In some embodiments, the ingredient is an oil, a probiotic, a botanical, an herbal extract, a digestive enzyme, a vitamin, a carotenoid, a collagen, a medicament, or a combination thereof.
  • In some embodiments, the bottom of the diaphragm may be flattened. In some embodiments, the bottom of the diaphragm may be curved. In some embodiments, the bottom of the diaphragm may be substantially or partially flattened.
  • In some embodiments, the oil comprises an omega-3 oil and the ingredient is a multivitamin powder, or a multivitamin powder and coenzyme Q10.
  • In some embodiments, the oil comprises an omega-3 oil and the ingredient is a statin, or a statin and coenzyme Q10.
  • In some embodiments, the oil comprises an omega-3 oil and the ingredient is vitamin K2.
  • In some embodiments, the oil comprises alpha-linolenic acid and the ingredient is selected from chromium, or chromium and coenzyme Q10.
  • In some embodiments, the oil is saw palmetto oil and the ingredient is a liothyronine sodium (T3) powder.
  • In some embodiments, the oil is red palm oil, and the ingredient is selected from vitamin D, vitamin K2, a multivitamin or a combination thereof.
  • In some embodiments, the oil is an omega-3 oil, and the ingredient is selected from aspirin, a statin, or a combination thereof.
  • Some embodiments described herein are directed to a multi-compartment capsule comprising a body; a diaphragm, having two sidewalls and a bottom, extending into the body and defining a first compartment between an outer surface of the diaphragm and an inner surface of the body, adapted to hold an ingredient; and a cap mounted to an outer surface of the body and opposed to the diaphragm, and defining a second compartment between an inner surface of the diaphragm and the cap, adapted to hold an oil; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body.
  • In some embodiments, the second compartment is sealed to prevent oil leakage.
  • In some embodiments, the ingredient has increased bioavailability upon exposure to the oil.
  • DESCRIPTION OF THE FIGURES
  • FIG. 1 illustrates a cross-sectional view of a capsule of embodiments herein wherein the first (lower) compartment has a volume of about 423 mm3 and the second (upper) compartment has a volume of about 497 mm3, and wherein the first compartment comprises an oil and the second compartment comprises an ingredient.
  • FIG. 2 illustrates a cross-sectional view of a capsule of embodiments herein wherein the first (lower) compartment has a volume of 743 mm3 and the second (upper) compartment has a volume of 176 mm3, and wherein the first compartment comprises an oil and the second compartment comprises an ingredient.
  • FIG. 3 illustrates a cross-sectional view of a capsule of embodiments herein with a flattened bottom, wherein each compartment comprises a solid ingredient.
  • FIGS. 4A, 4B, and 4C illustrate standard and elongated TORPAC capsule sizes, which may be used in some embodiments described herein.
  • DETAILED DESCRIPTION
  • Before the present compositions and methods are described, it is to be understood that this invention is not limited to the particular processes, compositions, or methodologies described, as these may vary. It is also to be understood that the terminology used in the description is for the purpose of describing the particular versions or embodiments only, and is not intended to limit the scope of the present invention, which will be limited only by the appended claims. Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art. Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of embodiments of the present invention, the preferred methods, devices, and materials are now described. All publications mentioned herein are incorporated by reference in their entireties. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.
  • It must also be noted that as used herein and in the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, reference to “an ingredient” is a reference to one or more ingredients and equivalents thereof known to those skilled in the art, and so forth.
  • As used herein, the term “about” means plus or minus 10% of the numerical value of the number with which it is being used. Therefore, about 50 mg means in the range of 45 mg-55 mg.
  • The term “patient” or “subject” as used herein is an animal, particularly a human, suffering from an unwanted disease or condition that may be treated by the therapeutics and/or compositions described herein.
  • “Optional” or “optionally” means that the subsequently described event or circumstance may or may not occur, and that the description includes instances where the event occurs and instances where it does not.
  • Throughout the specification of the application, various terms are used such as “primary,” “secondary,” “first,” “second,” and the like. These terms are words of convenience used to distinguish between different elements, and such terms are not intended to limit how the different elements may be used.
  • As used herein, the term “medicament” or “therapeutic” means an agent used to treat, combat, ameliorate, prevent or improve an unwanted condition or disease of a subject.
  • A “therapeutically effective amount” or “effective amount” of a composition is an amount necessary or sufficient to achieve the desired result. The activity contemplated by the embodiments herein includes medically therapeutic, cosmetically therapeutic and/or prophylactic treatment, as appropriate. A therapeutically effective amount of the compound of embodiments herein is typically an amount such that when it is administered in a physiologically tolerable excipient composition, it is sufficient to achieve an effective systemic concentration or local concentration in or on the tissue to achieve the desired therapeutic or clinical outcome.
  • The terms “treat,” “treated,” or “treating,” as used herein, refer to therapeutic treatment, cosmetic treatment, and/or prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological condition, disorder, or disease, or to obtain beneficial or desired clinical results. For the purposes of this invention, beneficial or desired clinical results include, but are not limited to, alleviation of symptoms; diminishment of the extent of the condition, disorder, or disease; stabilization (i.e., not worsening) of the state of the condition, disorder, or disease; delay in onset or slowing of the progression of the condition, disorder, or disease; amelioration of the condition, disorder, or disease state; and remission (whether partial or total), whether detectable or undetectable, or enhancement or improvement of the condition, disorder, or disease. Treatment includes eliciting a clinically significant response without excessive levels of side effects.
  • As used herein, the term “consists of” or “consisting of” means that the formulation includes only the elements, steps, or ingredients specifically recited in the particular claimed embodiment or claim.
  • As used herein, the term “consisting essentially of” or “consists essentially of” means that the only active pharmaceutical ingredient in the formulation or method that treats the specified condition is the specifically recited therapeutic in the particular embodiment or claim.
  • Capsules are typically manufactured in certain standard sizes, such as TORPAC sizes, referred to as a capsule size designated by numerals, such as 000, 00, etc. Such capsules typically have two parts: a cap and a body, which are bonded or fitted together. One of the most common sizes is the 00 capsule. The typical size 00 capsule, in common with other capsules, has a standardized nominal volume. For instance, a size 00 capsule has a volume of approximately 0.95 milliliters. In some embodiments described below, the multi-compartment capsule is a size 00 capsule. In some embodiments, the capsule size may be size 000, size 0, size 1, size 2, size 3, size 4, or size 5, or any non-standard size in between these sizes. In some embodiments described below, the capsule size may be elongated (“EL”), such that the size may be, for example, 00 EL. In some embodiments, the elongation may be to any standard length or to a non-standard length. In some embodiments, the elongated capsule may add from about 50 mm3 to about 150 mm3 of additional volume to the first compartment, the second compartment, or a combination thereof. In some embodiments, the elongated capsule may add about 110 mm3 of additional volume to the first compartment, the second compartment, or a combination thereof. In some embodiments, if the diaphragm's diameter is reduced, it may be possible to insert a longer diaphragm into the capsule, thereby changing the available volumes in both the first and second compartments. In some embodiments, scaling the dimensions of the multi-compartment capsule described herein may result in a larger or smaller capsule with substantially the same ratios as described herein. In some embodiments, scaling the dimensions of the multi-compartment capsule described herein may result in a larger or smaller capsule with ratios different from those described herein.
  • Exemplary benefits of such two-compartment capsules may include increased patient compliance, a double-chamber controlled release, increased efficacy or bioavailability of ingredients due to co-administration, increased stability, and the ability to formulate difficult combinations of ingredients into one capsule, such as incompatible actives which can now be co-administered.
  • For some applications, it may be advantageous to deliver one or more ingredients in the form of a capsule with two compartments. For some applications, it may advantageous for the one or more ingredients delivered in such a capsule to be ingredients which have improved bioavailability when dissolved in one or more oils.
  • Embodiments described herein are directed to a multi-compartment capsule comprising a body; a diaphragm, having two sidewalls and a bottom, extending into the body and defining a first compartment between an outer surface of the diaphragm and an inner surface of the body; and a cap mounted to an outer surface of the body and opposed to the diaphragm, and defining a second compartment between an inner surface of the diaphragm and the cap; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body. In some embodiments, the capsule is a size 00 capsule.
  • In some embodiments, the multi-compartment capsule may comprise a body; a diaphragm, having two sidewalls and a bottom, extending into the body and forming a first compartment defined by a first surface of the diaphragm and the body; and a cap mounted to the body and opposed to the diaphragm, the cap forming a second compartment defined by an opposing surface of the diaphragm and the cap; wherein the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body; and wherein the first compartment and the second compartment are each adapted to hold one or more solid ingredients. In some embodiments, the first compartment is hermetically sealed by the diaphragm. In some embodiments, the one or more solid ingredients comprises an oil, a liquid, a powder, a granule, a semi-solid, a microbead, a beadlet, or a combination thereof.
  • In some embodiments, the bottom of the diaphragm may be flattened. A flatter bottom may allow for more volume in the lower compartment. In some embodiments, the bottom of the diaphragm may be curved. In some embodiments, the bottom of the diaphragm may be substantially or partially flattened.
  • In some embodiments, the contents of the first compartment and the contents of the second compartment may be released simultaneously. This simultaneous release may occur because each end of the multi-compartment capsule comprises the same or substantially the same material composition and thickness, such that when the capsule is digested, both compartments are degraded simultaneously. This simultaneous release may be advantageous in some embodiments wherein the contents of the first compartment and the contents of the second compartment may provide improved bioavailability or other synergistic effects when combined by such a release.
  • In some embodiments, the first compartment comprises an oil. In some embodiments, the second compartment comprises an ingredient. In some embodiments, the second ingredient is adapted to hold an ingredient which has increased bioavailability after exposure to the oil. In some embodiments, the first compartment comprises an ingredient having increased bioavailability after exposure to oil and the second compartment comprises an oil. Exemplary formulations described below could be used with oil in either compartment.
  • In some embodiments, the two sidewalls of the diaphragm extend along the inner surface of the body and are aligned with an open end of the body. In some embodiments, the capsule is a size 00 capsule. In some embodiments, the first compartment is hermetically sealed by the insertion and sealing of the diaphragm into the capsule body.
  • In some embodiments, the bottom of the diaphragm may be flattened. In some embodiments, the bottom of the diaphragm may be curved. In some embodiments, the bottom of the diaphragm may be substantially or partially flattened.
  • In some embodiments, the oil is selected from the group consisting of omega-3 oil, red palm oil, fish oil, krill oil, walnut oil, saw palmetto oil, castor oil, garlic oil, flaxseed oil, canola oil, soybean oil, cannabis oil, argan oil, coconut oil, peppermint oil, evening primrose oil, oregano oil, emu oil, cod liver oil, algae oil, grape seed oil, rose oil, clove oil, vitamin E oil, blueberry seed oil, raspberry seed oil, pumpkin seed oil, hemp oil, alpha-linolenic acid, conjugated linoleic acid, docosahexaenoic acid, ginger oil, lavender oil, and combinations thereof.
  • In some embodiments, the omega-3 oil is selected from the group consisting of alpha-linolenic acid, docosahexaenoic acid, eicosapentaenoic acid, krill oil, fish oil, walnut oil, flaxseed oil, canola oil, soybean oil, and combinations thereof. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg.
  • In some embodiments, the oil may comprise a form or derivative of vitamin E In some embodiments, the oil may comprise from about 10 mg to about 500 mg of a form or derivative of vitamin E In some embodiments, the form or derivative of vitamin E may be a tocotrienol, such as, for example, alpha tocotrienol, beta tocotrienol, gamma tocotrienol, delta tocotrienol, or any combination thereof.
  • In some embodiments, the ingredient is an oil, a liquid, a powder, a granule, a semi-solid, a gel, a beadlet, a microbead, a liquid, or a combination thereof. In some embodiments, the ingredient is an oil, a probiotic, a botanical, an herbal extract, a digestive enzyme, a vitamin, a carotenoid, a collagen, a medicament, or a combination thereof. In some embodiments, the ingredient may comprise alpha-carotene, beta-carotene, biotin, cadmium, caffeine, calcium, cinnamon, copper, curcumin, dexmethylphenidate, dicalcium phosphate, docosahexaenoic acid, folic acid, frankincense, glucosamine, gymnema, gymnema extract, iodine, iron, linoleic acid, lipoic acid, LOWAT, lutein, lycopene, magnesium, magnesium stearate, manganese, melatonin, molybdenum, niacin, oleic acid, palmitic, panthothenic acid, passion flower, phosphorus, a plant sterol, resvida, selenium, squalene, ginseng, tocopherols, vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin C, vitamin K, zinc, or a combination thereof.
  • In some embodiments, the ingredient comprises a pharmaceutical agent. In some embodiments, the pharmaceutical agent is selected from the group consisting of aspirin, a statin, ipriflavone, cohosh, castus, coenzyme Q10 (CoQ10), gauifenesin, althea root, antimony pentasulfide, creosote, guaiacolsulfonate, ipecacuanha (syrup of ipecac), levoverbenone, potassium iodide, senega, tyloxapol, ammonium chloride, salbutamol, albuterol, levosalbutamol, levalbuterol, pirbuterol, epinephrine, ephedrine, terbutaline, salmeterol, clenbuterol, formoterol, bambuerol, indacaterol, ephrinesulfate, ticlopidine, clopidogrel, prasugrel, ticagrelor, cilostazol, vorapaxar, trifusal, dipyridamole, a tocotrienol, triiodothyronine (T3), liothyronine sodium, and combinations thereof.
  • In some embodiments, the ingredient comprises aspirin. In some embodiments, the aspirin comprises from about 10 mg to about 500 mg. In some embodiments, the aspirin comprises from about 81 mg to about 324 mg. In some embodiments, one of the first or second compartment comprises aspirin in an amount of about 10 mg to about 500 mg.
  • In some embodiments, the ingredient comprises a statin. The statin may be selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, and combinations thereof. The statin may be in an amount of about 1 mg to about 100 mg. In some embodiments, the statin may be in an amount of about 5 mg to about 40 mg. In some embodiments, one of the first or second compartment comprises a statin in an amount of about 1 mg to about 100 mg.
  • In some embodiments, the first compartment comprises aspirin in an amount of about 10 mg to about 500 mg and the second compartment comprises an oil in an amount of about 10 mg to about 2000 mg. In some embodiments, the oil is an omega-3 oil.
  • In some embodiments, the capsule may include omega-3 oil with or without red palm oil in the first compartment, and CoQ10 in the second compartment. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The red palm oil may be in an amount of about 10 mg to about 2000 mg. The CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • In some embodiments, the oil comprises an omega-3 oil and the ingredient is a multivitamin, or a multivitamin and coenzyme Q10. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The CoQ10 may be in an amount of about 10 mg to about 1000 mg. The multivitamin may be in an amount of about 1 mg to about 5000 mg.
  • In some embodiments, the oil comprises an omega-3 oil and the ingredient is a statin, or a statin and coenzyme Q10. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The statin in an amount of about 1 mg to about 100 mg. The CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • In some embodiments, the oil comprises an omega-3 oil and the ingredient is vitamin K2. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The vitamin K2 may be in an amount of about 10 mcg to about 1000 mcg.
  • In some embodiments, the oil comprises alpha-linolenic acid and the ingredient is selected from chromium, or chromium and coenzyme Q10. The alpha linolenic acid may be in an amount of about 10 mg to about 500 mg. The chromium may be in an amount of about 10 mcg to about 1000 mcg. The CoQ10 may be in an amount of about 10 mg to about 1000 mg.
  • In some embodiments, the oil is saw palmetto oil and the ingredient is liothyronine sodium (T3). The saw palmetto oil may be in an amount of about 10 mg to about 1000 mg. The liothyronine sodium may be in an amount of about 5 mcg to about 500 mcg.
  • In some embodiments, the oil is red palm oil, and the ingredient is selected from vitamin D, vitamin K2, a multivitamin or a combination thereof. The red palm oil may be in an amount of about 10 mg to about 2000 mg. The vitamin D may be in an amount of about 10 IU to about 3000 IU. The vitamin K2 may be in an amount of about 10 mcg to about 1000 mcg. The multivitamin may be in an amount of about 1 mg to about 5000 mg.
  • In some embodiments, the oil is red palm oil, and the ingredient is selected from lutein, lycopene, biotin, selenium, selenium (methionine), zinc, zinc (glyconate), or a combination thereof. The red palm oil may be in an amount of about 10 mg to about 2000 mg. The lutein may be in an amount of about 1 mg to about 30 mg. The lycopene may be in an amount of about 1 mg to about 30 mg. The biotin may be in an amount of about 0.01 mg to about 10 mg. The selenium or selenium (methionine) may be in an amount of about 1 mcg to about 200 mcg. The zinc or zinc (glyconate) may be in an amount of about 1 mg to about 45 mg.
  • In some embodiments, the oil is an omega-3 oil and the ingredient is selected from frankincense, gymnema, gymnema extract, cinnamon, chromium, chromium (picolinate), vitamin B6, vitamin B12, or a combination thereof. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The frankincense may be in an amount of about 1 mg to about 500 mg. The gymnema or gymnema extract may be in an amount of about 10 mg to about 1000 mg. The cinnamon may be in an amount of about 10 mg to about 1000 mg. The chromium or chromium (picolinate) may be in an amount of about 10 mg to about 1000 mg. The vitamin B6 may be in an amount of about 10 mg to about 1000 mg. The vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg.
  • In some embodiments, the oil is an omega-3 oil, and the ingredient is selected from resvida, lipoic acid, CoQ10, folic acid, vitamin B6, vitamin B12, or a combination thereof. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The resvida may be in an amount of about 10 mg to about 1000 mg. The amount of lipoic acid may be in an amount of about 1 mg to about 1000 mg. The CoQ10 may be in an amount of about 10 mg to about 1000 mg. The folic acid may be in an amount of about 0.1 mcg to about 1000 mcg. The vitamin B6 may be in an amount of about 10 mg to about 1000 mg. The vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg.
  • In some embodiments, the oil is selected from krill oil, red palm oil, or a combination thereof, and the ingredient is selected from oleic acid, linoleic acid, tocotrienols, tocopherols, beta-carotene, alpha-carotene, squalene, a plant sterol, CoQ10, a multivitamin, or a combination thereof. The krill oil may be in an amount of about 10 mg to about 2000 mg. The red palm oil may be in an amount of about 10 mg to about 2000 mg. The oleic acid may be in an amount of about 10 mg to about 1000 mg. The linoleic acid may be in an amount of about 1 mg to about 1000 mg. The tocotrienols may be in an amount of about 1 mg to about 1000 mg. The tocopherols may be in an amount of about 1 mg to about 1000 mg. The beta-carotene may be in an amount of about 1 mg to about 1000 mg. The alpha-carotene may be in an amount of about 1 mg to about 1000 mg. The squalene may be in an amount of about 0.1 mg to about 1000 mg. The plant sterol may be in an amount of about 1 mg to about 1000 mg. The CoQ10 may be in an amount of about 0.01 mg to about 1000 mg. The multivitamin may be in an amount of about 1 mg to about 5000 mg.
  • In some embodiments, the oil is selected from krill oil, an omega-3 oil such as, for example, docosahexaenoic acid (DHA), or a combination thereof, and the ingredient is selected from vitamin C, zinc, dicalcium phosphate, vitamin D, vitamin K, magnesium, calcium, or a combination thereof. The krill oil may be in an amount of about 10 mg to about 2000 mg. The DHA may be in an amount of about 10 mg to about 2000 mg. The vitamin C may be in an amount of about 1 mg to about 1000 mg. The zinc may be in an amount of about 1 mg to about 1000 mg. The dicalcium phosphate may be in an amount of about 1 mg to about 1000 mg. The vitamin D may be in an amount of about 10 IU to about 3000 IU. The vitamin K may be in an amount of about 10 mcg to about 1000 mcg. The magnesium may be in an amount of about 0.1 mg to about 1000 mg. The calcium may be in an amount of about 1 mg to about 1000 mg.
  • In some embodiments, the oil is krill oil, and the ingredient is selected from a multivitamin, CoQ10, vitamin A, vitamin D, vitamin D3, vitamin E, biotin, folic acid, niacin, panthothenic acid, vitamin B1, vitamin B2, vitamin B6, vitamin B12, vitamin C, vitamin K, calcium, chromium, copper, iodine, magnesium, magnesium stearate, manganese, molybdenum, phosphorus, selenium, zinc, or a combination thereof. The krill oil may be in an amount of about 10 mg to about 2000 mg. The multivitamin may be in an amount of about 1 mg to about 5000 mg. The CoQ10 may be in an amount of about 0.01 mg to about 1000 mg. The vitamin A may be in an amount of about 10 IU to about 4000 IU. The vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU. The vitamin E may be in amount of about 10 IU to about 3000 IU. The biotin may be in an amount of about 10 mcg to about 1000 mcg. The folic acid may be in an amount of about 0.1 mcg to about 1000 mcg. The niacin may be in an amount of about 1 mg to about 1000 mg. The panthothenic acid may be in an amount of about 1 mg to about 1000 mg. The vitamin B1 may be in an amount of about 1 mg to about 1000 mg. The vitamin B2 may be in an amount of about 1 mg to about 1000 mg. The vitamin B2 may be in an amount of about 1 mg to about 1000 mg. The vitamin B6 may be in an amount of about 1 mg to about 1000 mg. The vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg. The vitamin C may be in an amount of about 1 mg to about 1000 mg. The vitamin K may be in an amount of about 10 mcg to about 1000 mcg. The calcium may be in an amount of about 1 mg to about 1000 mg. The chromium may be in an amount of about 1 mcg to about 1000 mcg. The copper may be in an amount of about 0.1 mg to about 100 mg. The iodine may be in an amount of about 0.01 mg to about 100 mg. The magnesium may be in an amount of about 0.1 mg to about 1000 mg. The magnesium stearate may be in an amount of about 0.1 mg to about 1000 mg. The manganese may be in an amount of about 0.1 mg to about 100 mg. The molybdenum may be in an amount of about 1 mcg to about 1000 mcg. The phosphorous may be in an amount of about 1 mg to about 100 mg. The selenium may be in an amount of about 1 mcg to about 200 mcg. The zinc may be in an amount of about 1 mg to about 1000 mg.
  • In some embodiments, the oil is red palm oil, and the ingredient is selected from ginseng, CoQ10, vitamin B12, caffeine, caffeine beadlets, or a combination thereof. The red palm oil may be in an amount of about 10 mg to about 2000 mg. The ginseng may be in an amount of about 10 mg to about 1000 mg. The CoQ10 may be in an amount of about 0.01 mg to about 1000 mg. The vitamin B12 may be in an amount of about 10 mcg to about 1000 mcg. The caffeine or caffeine beadlets may be in an amount of about 1 mg to about 1000 mg.
  • In some embodiments, the oil is krill oil, and the ingredient is selected from vitamin D, vitamin D3, calcium, or a combination thereof. The krill oil may be in an amount of about 10 mg to about 2000 mg. The vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU. The calcium may be in an amount of about 1 mg to about 1000 mg.
  • In some embodiments, the oil is an omega-3 oil, and the ingredient is a probiotic. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The probiotic may be in an amount of about 1 million to about 100 million CFUs.
  • In some embodiments, the oil is krill oil, and the ingredient is selected from vitamin K2, glucosamine, collagen, UC2 collagen, or a combination thereof. The krill oil may be in an amount of about 10 mg to about 2000 mg. The vitamin K2 may be in an amount of about 0.01 mg to about 100 mg. The glucosamine may be in an amount of about 10 mg to about 1000 mg. The collagen or UC2 collagen may be in amount of about 1 mg to about 1000 mg.
  • In some embodiments, the oil is an omega-3 oil such as, for example, alpha-linolenic acid (ALA), and the ingredient is selected from caffeine, caffeine beadlets, or a combination thereof. The ALA may be in an amount of about 10 mg to about 2000 mg. The caffeine or caffeine beadlets may be in an amount of about 1 mg to about 1000 mg.
  • In some embodiments, the oil is ginger oil and the ingredient is curcumin. The ginger oil may be in an amount of about 10 mg to about 2000 mg, and the circumin may be in an amount of about 10 mg to about 1000 mg.
  • In some embodiments, the oil is an omega-3 oil, and the ingredient is selected from vitamin D, vitamin D3, vitamin E, folic acid, vitamin B2, vitamin B6, vitamin B12, vitamin C, iron, dicalcium phosphate, or a combination thereof. The omega-3 oil may be in an amount of about 10 mg to about 2000 mg. The vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU. The vitamin E may be in an amount of about 1 IU to about 3000 IU. The folic acid may be in an amount of about 0.1 mcg to about 1000 mcg. The vitamin B2 may be in an amount of about 1 mg to about 1000 mg. The vitamin B6 may be in an amount of about 1 mg to about 1000 mg. The vitamin B12 may be in an amount of about 1 mcg to about 1000 mcg. The vitamin C may be in an amount of about 1 mg to about 1000 mg. The iron may be in an amount of about 1 mg to about 1000 mg. The dicalcium phosphate may be in an amount of about 1 mg to about 1000 mg.
  • In some embodiments, the oil is krill oil and the ingredient is selected from vitamin D, vitamin D3, vitamin K2, vitamin E, vitamin E tocotrienols, or a combination thereof. The krill oil may be in an amount of about 10 mg to about 2000 mg. The vitamin D or vitamin D3 may be in an amount of about 10 IU to about 3000 IU. The vitamin K2 may be in an amount of about 0.01 mg to about 100 mg. The vitamin E or vitamin E tocotrienols may be in an amount of about 10 mg to about 1000 mg.
  • In some embodiments, the oil is lavender oil, and the ingredient is selected from melatonin, passion flower, lemon, lemon extract, or a combination thereof. The lavender oil may be in an amount of about 10 mg to about 2000 mg. The melatonin may be in an amount of about 1 mg to about 1000 mg. The passion flower may be in an amount of about 10 mg to about 1000 mg. The lemon or lemon extract may be in an amount of about 10 mg to about 1000 mg.
  • In some embodiments, the oil is conjugated linoleic acid (CLA), and the ingredient is selected from piper betle leaf, dolichos bilforus seed extract, or a combination thereof, such as LOWAT. The CLA may be in an amount of about 10 mg to about 2000 mg. The piper betle leaf, dolichos bilforus seed extract, or combination thereof, such as LOWAT, may be in an amount of about 10 mg to about 1000 mg.
  • In some embodiments, the oil is krill oil, and the ingredient is aspirin. The krill oil may be in an amount of about 10 mg to about 2000 mg, and the aspirin may be in an amount of about 10 mg to about 500 mg.
  • In some embodiments, the first compartment and the second compartment each has sufficient volume to administer a therapeutically effective dose of the oil and the ingredient, respectively.
  • Table 1 below lists some possible combinations of ingredients which may be found in some embodiments. It is to be understood that any of the ingredients within Table 1 may be found in any combination, and may be found in either compartment of the capsule described herein. It is to be further understood that the embodiments described in Table 1 are not meant to be limiting, but are merely illustrative.
  • TABLE 1
    First compartment Second compartment
    About 10 mg to about 500 mg of aspirin About 10 mg to about 2000 mg of an oil
    About 10 mg to about 500 mg of aspirin About 10 mg to about 2000 mg of an
    omega-3 oil
    About 10 mg to about 2000 mg of an About 10 mg to about 1000 mg of CoQ10
    omega-3 oil; and/or
    About 10 mg to about 2000 mg of red
    palm oil
    About 10 mg to about 2000 mg of an About 1 mg to about 100 mg of a statin;
    omega-3 oil and/or
    About 10 mg to about 1000 mg of CoQ10
    About 10 mg to about 2000 mg of an About 10 mcg to about 1000 mcg of
    omega-3 oil vitamin K2
    About 10 mg to about 500 mg of alpha About 10 mcg to about 1000 mcg of
    linolenic acid chromium; and/or
    About 10 mg to about 1000 mg of CoQ10
    About 10 mg to about 1000 mg of saw About 5 mcg to about 500 mcg of
    palmetto oil liothyronine sodium
    About 10 mg to about 2000 mg of red About 10 IU to about 3000 IU of vitamin
    palm oil D; and/or
    About 10 mcg to about 1000 mcg of
    vitamin K2; and/or
    About 1 mg to about 5000 mg of a
    multivitamin
    About 10 mg to about 2000 mg krill oil About 10 mg to about 1000 mg of CoQ10;
    and/or
    About 1 mg to about 5000 mg of a
    multivitamin
    About 5 mcg to about 500 mcg of About 10 mg to about 1000 mg of vitamin
    triiodothyronine B6; and/or
    About 10 mcg to about 1000 mcg of
    vitamin B12
    About 10 mg to about 2000 mg of krill oil About 10 mcg to about 1000 mcg of
    vitamin K2
    About 10 mg to about 1000 mg of saw About 5 mcg to about 500 mcg of
    palmetto oil triiodothyronine
    About 10 mg to about 2000 mg of red About 1 mg to about 30 mg of lutein;
    palm oil and/or
    About 1 mg to about 30 mg of lycopene;
    and/or
    About 0.01 mg to about 10 mg of biotin;
    and/or
    About 1 mcg to about 200 mcg of
    selenium (methionine); and/or
    About 1 mg to about 45 mg of zinc
    (glyconate)
    About 10 mg to about 2000 mg of an About 1 mg to about 500 mg of
    omega-3 oil frankincense; and/or
    About 10 mg to about 1000 mg of
    gymnema or gymnema extract; and/or
    About 10 mg to about 1000 mg of
    cinnamon; and/or
    About 10 mg to about 1000 mg of
    chromium (picolinate); and/or
    About 10 mg to about 1000 mg of vitamin
    B6; and/or
    About 10 mcg to about 1000 mcg of
    vitamin B12
    About 10 mg to about 2000 mg of an About 10 mg to about 1000 mg of resvida;
    omega-3 oil and/or
    About 1 mg to about 1000 mg of lipoic
    acid; and/or
    About 10 mg to about 1000 mg of CoQ10;
    and/or
    About 0.1 mcg to about 1000 mcg of folic
    acid; and/or
    About 10 mg to about 1000 mg of vitamin
    B6; and/or
    About 10 mcg to about 1000 mcg of
    vitamin B12
    About 10 mg to about 2000 mg of krill oil; About 10 mg to about 1000 mg of oleic
    and/or acid; and/or
    About 10 mg to about 2000 mg of red About 1 mg to about 1000 mg of linoleic
    palm oil acid; and/or
    About 1 mg to about 1000 mg of
    tocotrienols; and/or
    About 1 mg to about 1000 mg of
    tocopherols; and/or
    About 1 mg to about 1000 mg beta-
    carotene; and/or
    About 1 mg to about 1000 mg alpha-
    carotene; and/or
    About 0.1 mg to about 1000 mg of
    squalene; and/or
    About 1 mg to about 1000 mg of a plant
    sterol; and/or
    About 0.01 mg to about 1000 mg of
    CoQ10; and/or
    About 1 mg to about 5000 mg of a
    multivitamin
    About 10 mg to about 2000 mg of krill oil; About 1 mg to about 1000 mg of vitamin
    and/or C; and/or
    About 10 mg to about 2000 mg of an About 1 mg to about 1000 mg of zinc;
    omega-3 oil, such as, for example, and/or
    docosahexaenoic acid (DHA) About 1 mg to about 1000 mg of
    dicalcium phosphate; and/or
    About 10 IU to about 3000 IU of vitamin
    D; and/or
    About 10 mcg to about 1000 mcg of
    vitamin K; and/or
    About 0.1 mg to about 1000 mg of
    magnesium; and/or
    About 1 mg to about 1000 mg of calcium
    About 10 mg to about 2000 mg of krill oil About 1 mg to about 5000 mg of a
    multivitamin; and/or
    About 0.01 mg to about 1000 mg of
    CoQ10; and/or
    About 10 IU to about 4000 IU of vitamin
    A; and/or
    About 10 IU to about 3000 IU of vitamin
    D or vitamin D3; and/or
    About 10 IU to about 3000 IU of vitamin
    E; and/or
    About 10 mcg to about 1000 mcg of
    biotin; and/or
    About 0.1 mcg to about 1000 mcg of folic
    acid; and/or
    About 1 mg to about 1000 mg of niacin;
    and/or
    About 1 mg to about 1000 mg of
    panthothenic acid; and/or
    About 1 mg to about 1000 mg of vitamin
    B1; and/or
    About 1 mg to about 1000 mg of vitamin
    B2; and/or
    About 1 mg to about 1000 mg of vitamin
    B6; and/or
    About 10 mcg to about 1000 mcg of
    vitamin B12; and/or
    About 1 mg to about 1000 mg of vitamin
    C; and/or
    About 10 mcg to about 1000 mcg of
    vitamin K; and/or
    About 1 mg to about 1000 mg of calcium;
    and/or
    About 1 mcg to about 1000 mcg of
    chromium; and/or
    About 0.1 mg to about 100 mg of copper;
    and/or
    About 0.01 mg to about 100 mg of iodine;
    and/or
    About 0.1 mg to about 1000 mg of
    magnesium; and/or
    About 0.1 mg to about 1000 mg of
    magnesium stearate; and/or
    About 0.1 mg to about 100 mg of
    manganese; and/or
    About 1 mcg to about 1000 mcg of
    molybdenum; and/or
    About 1 mg to about 100 mg of
    phosphorous; and/or
    About 1 mcg to about 200 mcg of
    selenium; and/or
    About 1 mg to about 1000 mg of zinc
    About 10 mg to about 2000 mg of red About 10 mg to about 1000 mg of
    palm oil ginseng; and/or
    About 0.01 mg to about 1000 mg of
    CoQ10; and/or
    About 10 mcg to about 1000 mcg of
    vitamin B12; and/or
    About 1 mg to about 1000 mg of caffeine
    About 10 mg to about 2000 mg of krill oil About 10 IU to about 3000 IU of vitamin
    D or vitamin D3; and/or
    About 1 mg to about 1000 mg of calcium
    About 10 mg to about 2000 mg of an About 1 million to about 100 billion CFUs
    omega-3 oil of a probiotic
    About 10 mg to about 2000 mg of krill oil About 0.01 mg to about 100 mg of
    vitamin K2; and/or
    About 10 mg to about 1000 mg of
    glucosamine; and/or
    About 1 mg to about 1000 mg of UC2
    collagen
    About 10 mg to about 2000 mg of an About 1 mg to about 1000 mg of caffeine
    omega-3 oil, such as, for example, or caffeine beadlets
    alpha-linolenic acid (ALA)
    About 10 mg to about 2000 mg of ginger About 10 mg to about 1000 mg of
    oil curcumin
    About 10 mg to about 2000 mg of an About 10 IU to about 3000 IU of vitamin
    omega-3 oil D or vitamin D3; and/or
    About 1 IU to about 3000 IU of vitamin
    E; and/or
    About 0.1 mcg to about 1000 mcg of folic
    acid; and/or
    About 1 mg to about 1000 mg of vitamin
    B2; and/or
    About 1 mg to about 1000 mg of vitamin
    B6; and/or
    About 1 mcg to about 1000 mcg of
    vitamin B12; and/or
    About 1 mg to about 1000 mg of vitamin
    C; and/or
    About 1 mg to about 1000 mg of iron;
    and/or
    About 1 mg to about 1000 mg of
    dicalcium phosphate
    About 10 mg to about 2000 mg of krill oil About 10 IU to about 3000 IU of vitamin
    D or vitamin D3; and/or
    About 0.01 mg to about 100 mg of
    vitamin K2; and/or
    About 10 mg to about 1000 mg of vitamin
    E tocotrienols
    About 10 mg to about 2000 mg of About 1 mg to about 1000 mg of
    lavender oil melatonin; and/or
    About 10 mg to about 1000 mg of passion
    flower; and/or
    About 10 mg to about 1000 mg of lemon
    or lemon extract
    About 10 mg to about 2000 mg of About 10 mg to about 1000 mg of a
    conjugated linoleic acid (CLA) combination of piper betle leaf and/or
    dolichos biflorus seed extract, such as
    LOWAT
    About 10 mg to about 2000 mg of krill oil About 10 mg to about 500 mg of aspirin
  • Table 2 below shows various dimensions of standard and elongated TORPAC capsule sizes, which may be used in some embodiments described herein.
  • TABLE 2
    CAPSULE SIZE 000 00E 00 00LQ 0E 0 1 2 3 4
    WEIGHT
    Average Weight (mg) 158 130 123 132 107 99 76 61 48 38
    tolerance ±10 ±10 ±7 ±4 ±7 ±6 ±5 ±4 ±3 ±3
    CAPACITY
    Volume Capacity (ml) 1.37 1.02 0.95 0.95 0.77 0.68 0.48 0.36 0.27 0.20
    density of dosing powder Weight Capacity (mg)
    0.6 g/ml 822 612 570 570 462 408 288 216 162 120
    0.8 g/ml 1096 816 760 760 616 544 384 288 216 160
    1.0 g/ml 1370 1020 950 950 770 680 480 360 270 200
    1.2 g/ml 1644 1224 1140 1140 924 816 576 432 324 240
    OVERALL CLOSED
    LENGTH
    (mm) 26 25.4 23.4 23.4 23.4 21.6 19.4 17.6 15.7 14.3
    tolerance ±0.3 ±0.3 ±0.3 ±0.3 ±0.3 ±0.3 ±0.3 ±0.3 ±0.3 ±0.3
    (inches) 1.024 1 0.921 0.921 0.921 0.85 0.764 0.693 0.618 0.563
    tolerance ±0.012 ±0.012 ±0.012 ±0.012 ±0.012 ±0.012 ±0.012 ±0.012 ±0.012 ±0.012
    INDIVIDUAL LENGTHS
    (CAP & BODY)
    CAP (mm) 12.9 12.94 11.8 11.8 11.9 10.85 9.85 8.8 8 7.2
    tolerance ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35
    BODY (mm) 21.9 22.38 20.1 20.1 20 18.45 16.4 15.15 13.45 12.1
    tolerance ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35 ±0.35
    CAP (inches) 0.508 0.509 0.464 0.464 0.468 0.427 0.388 0.346 0.315 0.283
    tolerance ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014
    BODY (inches) 0.862 0.881 0.791 0.791 0.787 0.726 0.646 0.596 0.529 0.476
    tolerance ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014 ±0.014
    EXTERNAL DIAMETER
    CAP (mm) 9.94 8.58 8.56 8.56 7.66 7.65 6.96 6.39 5.85 5.33
    BODY (mm) 9.55 8.25 8.23 8.23 7.35 7.35 6.63 6.12 5.60 5.08
    CAP (inches) 0.391 0.338 0.337 0.337 0.302 0.301 0.274 0.252 0.23 0.21
    BODY (inches) 0.376 0.325 0.324 0.324 0.289 0.289 0.261 0.241 0.22 0.2
    Recommended Storage Conditions: 59°-77° F./15°-25° C. RH 35-65%
  • Table 3 below shows additional dimensions of standard and elongated TORPAC capsule sizes, which may be used in some embodiments described herein.
  • TABLE 3
    Typical Fill Weights
    (mg)
    Actual Fill Weights
    may vary and depend
    on powder Single Weight
    characteristics Locked Cut Wall (Avg. of
    Powder Density Volume Length External Length Thickness 100)
    0.45 0.70 1.00 Theoretical +/−0.76 Tolerance Diam. +/−0.51 +/−0.03 +/−10%
    Size Light Typical Heavy (ml) (mm) Component (mm) (mm) (mm) (mg)
    000 615 960 1370 1.37 26.14 Cap 9.91 12.95 0.112 163
    Body 9.55 22.20 0.110
    00 430 665 950 0.95 23.30 Cap 8.53 11.74 0.109 118
    Body 8.18 20.22 0.107
    0 305 475 680 0.68 21.70 Cap 7.65 10.72 0.107 96
    Body 7.34 18.44 0.104
    1 225 350 500 0.50 19.40 Cap 6.91 9.78 0.104 76
    Body 6.63 16.61 0.102
    2 165 260 370 0.37 18.00 Cap 6.35 8.94 0.102 61
    Body 6.07 15.27 0.099
    3 135 210 300 0.30 15.90 Cap 5.82 8.08 0.092 48
    Body 5.56 13.59 0.890
    4 95 145 210 0.21 14.30 Cap 5.31 7.21 0.096 38
    Body 5.05 12.19 0.091
    5 60 90 130 0.13 11.10 Cap 4.91 6.20 0.089 28
    Body 4.68 9.32 0.086
  • Although the present invention has been described in considerable detail with reference to certain preferred embodiments thereof, other versions are possible. Therefore, the spirit and scope of the appended claims should not be limited to the description and the preferred versions contained within this specification. Modifications and improvements to the disclosed embodiments will be apparent to those skilled in the art in light of this disclosure, and are intended to fall within the scope of the pending claims.

Claims (27)

1.-22. (canceled)
23. A multi-compartment capsule comprising:
a body comprising an open end, a closed end, and inner surface, and an outer surface;
a diaphragm having a bottom and one or more peripheral sidewalls extending from the bottom, wherein the one or more peripheral sidewalls contact the body to form a first liquid-tight compartment between the diaphragm and the closed end of the body; and
a cap contacting the body at the open end to form a second liquid-tight compartment between the diaphragm and the cap,
wherein (i) a first of the first liquid-tight compartment and the second liquid-tight compartment contains an oil, and (ii) a second of the first liquid-tight compartment and the second liquid-tight compartment contains an oil-soluble ingredient, and
wherein the first liquid-tight compartment and the second liquid-tight compartment are configured to simultaneously release the oil and the oil-soluble ingredient during digestion of the multi-compartment capsule.
24. The multi-compartment capsule of claim 23, wherein the one or more peripheral sidewalls contact the body to form a hermetic seal between the first liquid-tight compartment and the second liquid-tight compartment.
25. The multi-compartment capsule of claim 23, wherein the oil-soluble ingredient is selected from the group consisting of a powder, a granule, a semi-solid, a beadlet, a microbead, and a combination thereof.
26. The multi-compartment capsule of claim 23, wherein the oil comprises an omega-3 oil comprising an eicosapentaenoic acid and the oil-soluble ingredient comprises a statin.
27. The multi-compartment capsule of claim 23, wherein the oil is selected from the group consisting of a cannabis oil and hemp oil, and
wherein the oil-soluble ingredient comprises an herbal extract.
28. The multi-compartment capsule of claim 23, wherein the one or more peripheral sidewalls contact the inner surface of the body to form the first liquid-tight compartment.
29. The multi-compartment capsule of claim 23, wherein the cap contacts the outer surface of the body to form the second liquid-tight compartment.
30. The multi-compartment capsule of claim 23, wherein at least a portion of the body and at least a portion of the cap comprise substantially the same material and substantially the same thickness.
31. The multi-compartment capsule of claim 23, wherein the oil is selected from the group consisting of omega-3 oil, red palm oil, fish oil, krill oil, walnut oil, saw palmetto oil, castor oil, garlic oil, flaxseed oil, canola oil, soybean oil, cannabis oil, argan oil, coconut oil, peppermint oil, evening primrose oil, oregano oil, emu oil, cod liver oil, algae oil, grape seed oil, rose oil, clove oil, vitamin E oil, blueberry seed oil, raspberry seed oil, pumpkin seed oil, hemp oil, alpha-linolenic acid, conjugated linoleic acid, docosahexaenoic acid, eicosapentaenoic acid, ginger oil, lavender oil, and combinations thereof.
32. A multi-compartment capsule comprising:
a body comprising an open end, a closed end, and inner surface, and an outer surface;
a diaphragm having a bottom and one or more peripheral sidewalls extending from the bottom, wherein the one or more peripheral sidewalls contact the body to form a first liquid-tight compartment between the diaphragm and the closed end of the body; and
a cap contacting the body at the open end to form a second liquid-tight compartment between the diaphragm and the cap,
wherein (i) a first of the first liquid-tight compartment and the second liquid-tight compartment contains an oil, and (ii) a second of the first liquid-tight compartment and the second liquid-tight compartment contains an oil-suspendable ingredient, and
wherein the first liquid-tight compartment and the second liquid-tight compartment are configured to simultaneously release the oil and the oil-suspendable ingredient during digestion of the multi-compartment capsule.
33. The multi-compartment capsule of claim 32, wherein the one or more peripheral sidewalls contact the body to form a hermetic seal between the first liquid-tight compartment and the second liquid-tight compartment.
34. The multi-compartment capsule of claim 32, wherein the oil-suspendable ingredient is selected from the group consisting of a powder, a granule, a semi-solid, a beadlet, a microbead, and a combination thereof.
35. The multi-compartment capsule of claim 32, wherein the one or more peripheral sidewalls contact the inner surface of the body to form the first liquid-tight compartment.
36. The multi-compartment capsule of claim 32, wherein the cap contacts the outer surface of the body to form the second liquid-tight compartment.
37. The multi-compartment capsule of claim 32, wherein at least a portion of the body and at least a portion of the cap comprise substantially the same material and substantially the same thickness.
38. The multi-compartment capsule of claim 32, wherein the oil is selected from the group consisting of omega-3 oil, red palm oil, fish oil, krill oil, walnut oil, saw palmetto oil, castor oil, garlic oil, flaxseed oil, canola oil, soybean oil, cannabis oil, argan oil, coconut oil, peppermint oil, evening primrose oil, oregano oil, emu oil, cod liver oil, algae oil, grape seed oil, rose oil, clove oil, vitamin E oil, blueberry seed oil, raspberry seed oil, pumpkin seed oil, hemp oil, alpha-linolenic acid, conjugated linoleic acid, docosahexaenoic acid, eicosapentaenoic acid, ginger oil, lavender oil, and combinations thereof
39. A method of manufacturing a multi-compartment capsule, the method comprising:
providing a body comprising an open end, a closed end, and inner surface, and an outer surface;
inserting an oil within the body such that the oil is adjacent the closed end;
inserting a diaphragm within the body, wherein the diaphragm comprises a bottom and one or more peripheral sidewalls extending from the bottom that contact the body to form a first liquid-tight compartment between the diaphragm and the closed end of the body, wherein the oil is contained with the first liquid-tight compartment;
inserting an oil-soluble ingredient within the diaphragm such that the oil-soluble ingredient is adjacent the bottom;
mounting a cap on the body at the open end to form a second liquid-tight compartment between the diaphragm and the cap, wherein the oil-soluble ingredient is contained with the second liquid-tight compartment,
wherein the first liquid-tight compartment and the second liquid-tight compartment are configured to simultaneously release the oil and the oil-soluble ingredient during digestion of the multi-compartment capsule.
40. A method of manufacturing a multi-compartment capsule, the method comprising:
providing a body comprising an open end, a closed end, and inner surface, and an outer surface;
inserting an oil within the body such that the oil is adjacent the closed end;
inserting a diaphragm within the body, wherein the diaphragm comprises a bottom and one or more peripheral sidewalls extending from the bottom that contact the body to form a first liquid-tight compartment between the diaphragm and the closed end of the body, wherein the oil is contained with the first liquid-tight compartment;
inserting an oil-suspendable ingredient within the diaphragm such that the oil-suspendable ingredient is adjacent the bottom;
mounting a cap on the body at the open end to form a second liquid-tight compartment between the diaphragm and the cap, wherein the oil-suspendable ingredient is contained with the second liquid-tight compartment,
wherein the first liquid-tight compartment and the second liquid-tight compartment are configured to simultaneously release the oil and the oil-suspendable ingredient during digestion of the multi-compartment capsule.
41. A multi-compartment capsule comprising:
a body comprising an open end, a closed end, and inner surface, and an outer surface;
a diaphragm having a bottom and one or more peripheral sidewalls extending from the bottom, wherein the one or more peripheral sidewalls contact the body to form a first liquid-tight compartment between the diaphragm and the closed end of the body; and
a cap contacting the body at the open end to form a second liquid-tight compartment between the diaphragm and the cap,
wherein (i) a first of the first liquid-tight compartment and the second liquid-tight compartment contains a primary ingredient, and (ii) a second of the first liquid-tight compartment and the second liquid-tight compartment contains a secondary ingredient, and
wherein the first liquid-tight compartment and the second liquid-tight compartment are configured to simultaneously release the primary ingredient and the secondary ingredient during digestion of the multi-compartment capsule.
42. The multi-compartment capsule of claim 41, wherein the secondary ingredient improves bioavailability of the primary ingredient when simultaneously released during digestion of the multi-compartment capsule.
43. The multi-compartment capsule of claim 42, wherein the secondary ingredient increases absorption of the primary ingredient during or after digestion of the multi-compartment capsule.
44. The multi-compartment capsule of claim 41, wherein the primary ingredient comprises curcumin and the secondary ingredient comprises piper or a component thereof.
45. The multi-compartment capsule of claim 44, wherein the secondary ingredient comprises piper betle leaf.
46. The multi-compartment capsule of claim 41, wherein the primary ingredient is selected from the group consisting of zinc and copper, and
wherein the secondary ingredient comprises vitamin C.
47. The multi-compartment capsule of claim 41, wherein the primary ingredient is selected from the group consisting of vitamin D3, and
wherein the secondary ingredient comprises magnesium.
48. The multi-compartment capsule of claim 41, wherein each of the primary ingredient and the secondary ingredient is selected from the group consisting of an oil, a liquid, a powder, a granule, a semi-solid, a gel, a beadlet, a microbead, and a combination thereof.
US17/488,787 2015-10-09 2021-09-29 Capsule with internal diaphragm for improved bioavailability Abandoned US20220160641A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US17/488,787 US20220160641A1 (en) 2015-10-09 2021-09-29 Capsule with internal diaphragm for improved bioavailability

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562239435P 2015-10-09 2015-10-09
US201562239454P 2015-10-09 2015-10-09
US201562239442P 2015-10-09 2015-10-09
PCT/US2016/056285 WO2017062954A1 (en) 2015-10-09 2016-10-10 Capsule with internal diaphragm for improved bioavailability
US201815767010A 2018-04-09 2018-04-09
US17/488,787 US20220160641A1 (en) 2015-10-09 2021-09-29 Capsule with internal diaphragm for improved bioavailability

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
US15/767,010 Continuation US11160759B1 (en) 2015-10-09 2016-10-10 Capsule with internal diaphragm for improved bioavailability
PCT/US2016/056285 Continuation WO2017062954A1 (en) 2015-10-09 2016-10-10 Capsule with internal diaphragm for improved bioavailability

Publications (1)

Publication Number Publication Date
US20220160641A1 true US20220160641A1 (en) 2022-05-26

Family

ID=58488624

Family Applications (4)

Application Number Title Priority Date Filing Date
US15/767,036 Active US11478429B2 (en) 2015-10-09 2016-10-10 Capsule with internal diaphragm and solid ingredients
US15/767,010 Active US11160759B1 (en) 2015-10-09 2016-10-10 Capsule with internal diaphragm for improved bioavailability
US15/766,976 Active US11357732B2 (en) 2015-10-09 2016-10-10 Capsule with volume-adjustable internal diaphragm
US17/488,787 Abandoned US20220160641A1 (en) 2015-10-09 2021-09-29 Capsule with internal diaphragm for improved bioavailability

Family Applications Before (3)

Application Number Title Priority Date Filing Date
US15/767,036 Active US11478429B2 (en) 2015-10-09 2016-10-10 Capsule with internal diaphragm and solid ingredients
US15/767,010 Active US11160759B1 (en) 2015-10-09 2016-10-10 Capsule with internal diaphragm for improved bioavailability
US15/766,976 Active US11357732B2 (en) 2015-10-09 2016-10-10 Capsule with volume-adjustable internal diaphragm

Country Status (4)

Country Link
US (4) US11478429B2 (en)
EP (3) EP3359131A4 (en)
CN (3) CN108472244A (en)
WO (3) WO2017062956A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062956A1 (en) 2015-10-09 2017-04-13 Binutra Incorporated Capsule with internal diaphragm and solid ingredients
US10716761B2 (en) 2017-07-24 2020-07-21 Alcresta Therapeutics, Inc. Ingestible medical delivery devices
GB2568238B (en) * 2017-11-01 2021-05-26 Sims Caroline Dietary powder composition comprising plant-based sources of fatty acids
CA3083592A1 (en) * 2017-12-01 2019-06-06 Healthy Option Consulting Inc. Soft dual chambered liquid-gel capsule and method to deliver sublingual and ingestible cannabis compositions
WO2019239436A1 (en) * 2018-06-14 2019-12-19 Alma Mater Studiorum - Universita' Di Bologna Electrospun fibers for a local release of an anti-inflammatory drug and a promyelinating drug
CN109337816A (en) * 2018-09-29 2019-02-15 昆明理工大学 A method of reducing molasses alcohol waste mash total nitrogen, total phosphorus and COD
US11547693B2 (en) 2019-07-29 2023-01-10 Matthias Rath Ascorbate in the prevention of statin induced vascular calcification
CN110898027A (en) * 2019-12-12 2020-03-24 陕西鹤鸣健康科技有限公司 Vitamin K2 (MK-7) soft capsule for promoting calcium in blood to enter bone and preparation method thereof
CN114790379A (en) * 2022-04-24 2022-07-26 西南石油大学 Double-chamber microcapsule for drilling fluid and preparation method and application thereof

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7610038A (en) * 1976-09-09 1978-03-13 Tapanahony N V Multichambered capsule for therapeutically active substances - has chambers of different solubility with contents differing quantitatively and qualitatively
GB2070553A (en) * 1980-02-29 1981-09-09 Automatisme & Technique Process and apparatus for filling and sealing hard gelatin capsules
US4415555A (en) * 1981-03-24 1983-11-15 Kyowa Chemical Industry C. Ltd. Composition and method for treating iron deficiency syndrome
US4917885A (en) * 1984-10-23 1990-04-17 Shin-Etsu Chemical Co., Ltd. Hard medicinal capsule
US5536506A (en) * 1995-02-24 1996-07-16 Sabinsa Corporation Use of piperine to increase the bioavailability of nutritional compounds
US20050175565A1 (en) * 2002-06-21 2005-08-11 L'oreal Use of taurine for the treatment of alopecia
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
US20080008750A1 (en) * 2004-12-28 2008-01-10 Shinji Tochio Band-Seals For Hard Capsules
GB2458467A (en) * 2008-03-18 2009-09-23 Ajit Lalvani Dietary supplement for maintenance of bone health
WO2013050973A1 (en) * 2011-10-06 2013-04-11 Market Demand Trading 767 Proprietary Limited A method and apparatus for manufacturing a capsule

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1510260A (en) 1921-06-30 1924-09-30 Lloyd W Cyrenius Capsule
US3066501A (en) * 1958-12-04 1962-12-04 Chelton Hong Kong Ltd Stringless necklace beads having rigid bodies with resilient sockets therein
US3927195A (en) * 1974-01-31 1975-12-16 Lilly Industries Ltd Production of capsules
US4339428A (en) 1980-08-18 1982-07-13 Bristol-Myers Company Capsule product containing high dosage of aspirin in powder or granulated form and alkaline tablet or pellet comprising magnesium carbonate, calcium carbonate and a magnesium dry component
US4748058A (en) * 1987-02-10 1988-05-31 Craig Jr Chester L Artificial tree
US5394980A (en) * 1987-06-30 1995-03-07 Tsai; Min H. Multicompartment mixing capsule
US5387421A (en) 1991-01-31 1995-02-07 Tsrl, Inc. Multi stage drug delivery system
US5223265A (en) * 1992-01-10 1993-06-29 Alza Corporation Osmotic device with delayed activation of drug delivery
ITMI20020731A1 (en) 2002-04-08 2003-10-08 Ibsa Inst Biochimique Sa PHARMACEUTICAL COMPOSITIONS FOR ACETYLSALICYLIC ACID AND OMEGA-3 OILS
US7670612B2 (en) 2002-04-10 2010-03-02 Innercap Technologies, Inc. Multi-phase, multi-compartment capsular delivery apparatus and methods for using same
MXPA05013147A (en) 2003-06-06 2006-03-17 Takeda Pharmaceutical Solid pharmaceutical preparation.
US20050123603A1 (en) 2003-09-26 2005-06-09 Natural Asa Natural menaquinone 7 compositions
JP2006050933A (en) * 2004-08-11 2006-02-23 Meiji Riken Kk Chlorella dietary supplement
US8444681B2 (en) * 2009-06-15 2013-05-21 Roger P. Jackson Polyaxial bone anchor with pop-on shank, friction fit retainer and winged insert
AU2006236345B2 (en) 2005-04-19 2011-03-31 Hill's Pet Nutrition, Inc. Methods and compositions for the prevention and treatment of kidney disease
US8784886B2 (en) 2006-03-09 2014-07-22 GlaxoSmithKline, LLC Coating capsules with active pharmaceutical ingredients
US8491888B2 (en) 2006-05-05 2013-07-23 Softgel Formulators, Inc. Highly absorbable coenzyme Q10 composition and method of producing same
WO2008006607A2 (en) 2006-07-14 2008-01-17 Nattopharma Asa Pharmaceutical and nutraceutical products comprising vitamin k2
US20080213320A1 (en) 2007-03-01 2008-09-04 Jeremy B. Eisenstein Compositions for treatment of gastro-esophageal reflux disorders
US20090087483A1 (en) * 2007-09-27 2009-04-02 Sison Raymundo A Oral dosage combination pharmaceutical packaging
EP2211820B1 (en) * 2007-10-19 2012-05-02 Capsugel Belgium NV Multi-compartmented container
US20120209339A1 (en) * 2011-02-11 2012-08-16 Daniel Scodary Device for spinal fusion
CA2855469A1 (en) 2011-04-22 2012-10-26 Paul Joseph FAERSTEIN Compositions and methods for nutritional supplementation
CN104703518B (en) * 2012-10-12 2018-05-22 雀巢产品技术援助有限公司 Culinary capsule with multi-compartment
CA2905367A1 (en) 2013-03-15 2014-09-25 Banner Life Sciences Llc Non-gelatin enteric soft capsules
US9139458B2 (en) 2013-03-15 2015-09-22 Janet Angel Compositions and methods of use
US9456987B2 (en) * 2013-04-03 2016-10-04 Binutra, Inc. Capsule with internal diaphragm
CN105307949A (en) 2013-06-19 2016-02-03 荷兰联合利华有限公司 Multi-compartment water-soluble capsules
EP2777802B1 (en) * 2013-12-03 2016-03-16 Capsugel Belgium NV Multi-compartment dosage form articles
WO2017062956A1 (en) 2015-10-09 2017-04-13 Binutra Incorporated Capsule with internal diaphragm and solid ingredients

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7610038A (en) * 1976-09-09 1978-03-13 Tapanahony N V Multichambered capsule for therapeutically active substances - has chambers of different solubility with contents differing quantitatively and qualitatively
GB2070553A (en) * 1980-02-29 1981-09-09 Automatisme & Technique Process and apparatus for filling and sealing hard gelatin capsules
US4415555A (en) * 1981-03-24 1983-11-15 Kyowa Chemical Industry C. Ltd. Composition and method for treating iron deficiency syndrome
US4917885A (en) * 1984-10-23 1990-04-17 Shin-Etsu Chemical Co., Ltd. Hard medicinal capsule
US5536506A (en) * 1995-02-24 1996-07-16 Sabinsa Corporation Use of piperine to increase the bioavailability of nutritional compounds
US20050175565A1 (en) * 2002-06-21 2005-08-11 L'oreal Use of taurine for the treatment of alopecia
US20060211762A1 (en) * 2004-12-06 2006-09-21 Rongen Roelof M Omega-3 fatty acids and dyslipidemic agent for lipid therapy
US20080008750A1 (en) * 2004-12-28 2008-01-10 Shinji Tochio Band-Seals For Hard Capsules
WO2006130027A1 (en) * 2005-05-31 2006-12-07 Santos Ma Joyce Bedelia B Aqueous oral liquid vitamin supplements containing stabilized vitamin c and metal ions
US20070053869A1 (en) * 2005-09-02 2007-03-08 Yuichi Sugiyama Formulation and method for enhancement of gastrointestinal absorption of pharmaceutical agents
GB2458467A (en) * 2008-03-18 2009-09-23 Ajit Lalvani Dietary supplement for maintenance of bone health
WO2013050973A1 (en) * 2011-10-06 2013-04-11 Market Demand Trading 767 Proprietary Limited A method and apparatus for manufacturing a capsule

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Pradhan et al. Journal of Pharmacognosy and Phytochemistry 2013 1(6):147-167). (Year: 2013) *
Shoba et al. Planta Medica 1998 64:353-356 (Year: 1998) *

Also Published As

Publication number Publication date
US11160759B1 (en) 2021-11-02
US20180289625A1 (en) 2018-10-11
CN108366970A (en) 2018-08-03
EP3359131A4 (en) 2019-05-01
US20180296489A1 (en) 2018-10-18
US11357732B2 (en) 2022-06-14
EP3359130A1 (en) 2018-08-15
WO2017062951A1 (en) 2017-04-13
CN108472244A (en) 2018-08-31
EP3359130A4 (en) 2019-05-01
CN108366959A (en) 2018-08-03
US11478429B2 (en) 2022-10-25
WO2017062954A1 (en) 2017-04-13
EP3359140A1 (en) 2018-08-15
EP3359131A1 (en) 2018-08-15
EP3359140A4 (en) 2019-05-01
WO2017062956A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
US20220160641A1 (en) Capsule with internal diaphragm for improved bioavailability
ES2496915T3 (en) Oral controlled release compositions comprising a vitamin D compound and a waxy support
JP6321060B2 (en) Multi-phase soft gel capsule, apparatus and method thereof
ES2807498T3 (en) Pharmaceutical formulations of statins and omega-3 fatty acids for encapsulation
US9168308B2 (en) Compositions and methods for nutritional supplementation
US20030194428A1 (en) Process for encapsulating multi-phase, multi-compartment capsules
US20090082738A1 (en) Natural Anti-Inflammatory Agents for Reducing Pain
JP2011068664A (en) Multi-phase, multi-compartment capsule system
CN107648268B (en) Application of krill oil for parenteral treatment
WO2011150312A1 (en) Tocotrienol compositions
ES2695503B2 (en) ENCAPSULATED FORMULATIONS
JP2023153863A (en) Compositions comprising 15-hepe and methods of using the same
KR20180066108A (en) Supplementary therapies and their supplies with 25-hydroxyvitamin D
JP2018534254A5 (en)
TW201028145A (en) Composition comprising hemp oil for treating topical diseases
de Freitas Cuba et al. Antioxidant agents: a future alternative approach in the prevention and treatment of radiation-induced oral mucositis
RU2010106225A (en) COMPOSITION AND METHOD USING A STABILIZED SENSITIVE INGREDIENT
CN108882722A (en) Release vitamin and mineral on time in edible oil
Mosalaei et al. Effect of oral zinc sulphate in prevention of radiation induced oropharyngeal mucositis during and after radiotherapy in patients with head and neck cancers
GB2512314A (en) Statin composition
US20130316017A1 (en) Oral Composition for the Treatment of Acne
JP2024061731A (en) Food supplements for use in prophylaxis and treatment of migraine
US20210228557A1 (en) Therapeutic compositions comprising coenzyme q10
RS59967B1 (en) Semisolid self-microemulsifying drug delivery systems with acyclovir filled in hard capsules, their preparation and application
Yohkoh 12 Drug–Dietary Supplement

Legal Events

Date Code Title Description
STPP Information on status: patent application and granting procedure in general

Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION

AS Assignment

Owner name: COMBOCAP, INC., NEW YORK

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LOUW, TOBIAS JOHAN;REEL/FRAME:060185/0601

Effective date: 20200915

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STPP Information on status: patent application and granting procedure in general

Free format text: RESPONSE TO NON-FINAL OFFICE ACTION ENTERED AND FORWARDED TO EXAMINER

STPP Information on status: patent application and granting procedure in general

Free format text: NON FINAL ACTION MAILED

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION